Market Research Logo

Rigel Pharmaceuticals Inc (RIGL) - Financial and Strategic SWOT Analysis Review

Rigel Pharmaceuticals Inc (RIGL) - Financial and Strategic SWOT Analysis Review

- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Rigel Pharmaceuticals Inc. (Rigel) is a biotechnology company that discovers and develops innovative small-molecule drugs for patients with immune disorders, hematological disorders, cancer and rare diseases. Its research activities focus on signaling pathways that are critical to disease mechanisms. Tavalisse (fostamatinib disodium hexahydrate), the company's first US FDA approved product is an oral spleen tyrosine kinase inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia. Rigel is also evaluating Fostamatinib for autoimmune hemolytic anemia and IgA nephropathy in Phase II trials. The company also has partnered clinical programs with Aclaris, BerGenBio, Daiichi, AstraZeneca and Bristol-Myers Squibb. Rigel is headquartered in South San Francisco, California, the US.

Rigel Pharmaceuticals Inc Key Recent Developments

May 01,2018: Rigel Reports First Quarter 2018 Financial Results
Mar 06,2018: Rigel Announces Fourth Quarter and Year End 2017 Financial Results and Provides Company Update
Dec 15,2017: Rigel Announces Departure of Chief Financial Officer
Nov 07,2017: Rigel Announces Third Quarter 2017 Financial Results and Provides Company Update
Nov 02,2017: Rigel Welcomes Gregg Lapointe to Board of Directors

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
Rigel Pharmaceuticals Inc - Key Facts
Rigel Pharmaceuticals Inc - Key Employees
Rigel Pharmaceuticals Inc - Key Employee Biographies
Rigel Pharmaceuticals Inc - Major Products and Services
Rigel Pharmaceuticals Inc - History
Rigel Pharmaceuticals Inc - Company Statement
Rigel Pharmaceuticals Inc - Locations And Subsidiaries
Head Office
Section 2 – Company Analysis
Rigel Pharmaceuticals Inc - Business Description
Rigel Pharmaceuticals Inc - Corporate Strategy
Rigel Pharmaceuticals Inc - SWOT Analysis
SWOT Analysis - Overview
Rigel Pharmaceuticals Inc - Strengths
Rigel Pharmaceuticals Inc - Weaknesses
Rigel Pharmaceuticals Inc - Opportunities
Rigel Pharmaceuticals Inc - Threats
Rigel Pharmaceuticals Inc - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Rigel Pharmaceuticals Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 06, 2018: Rigel Announces Fourth Quarter and Year End 2017 Financial Results and Provides Company Update
Dec 15, 2017: Rigel Announces Departure of Chief Financial Officer
Nov 07, 2017: Rigel Announces Third Quarter 2017 Financial Results and Provides Company Update
Nov 02, 2017: Rigel Welcomes Gregg Lapointe to Board of Directors
Aug 25, 2017: Rigel Welcomes Brian Kotzin, M.D. to Board of Directors
Aug 25, 2017: Rigel Welcomes Brian Kotzin, M.D. to Board of Directors
Aug 01, 2017: Rigel Announces Second Quarter 2017 Financial Results and Provides Company Update
May 02, 2017: Rigel Announces First Quarter 2017 Financial Results and Provides Company Update
Mar 07, 2017: Rigel Announces Fourth Quarter 2016 and Year End 2016 Financial Results
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
Rigel Pharmaceuticals Inc, Key Facts
Rigel Pharmaceuticals Inc, Key Employees
Rigel Pharmaceuticals Inc, Key Employee Biographies
Rigel Pharmaceuticals Inc, Major Products and Services
Rigel Pharmaceuticals Inc, History
Rigel Pharmaceuticals Inc, Key Competitors
Rigel Pharmaceuticals Inc, Ratios based on current share price
Rigel Pharmaceuticals Inc, Annual Ratios
Rigel Pharmaceuticals Inc, Annual Ratios (Cont...1)
Rigel Pharmaceuticals Inc, Interim Ratios
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Rigel Pharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Rigel Pharmaceuticals Inc, Performance Chart (2013 - 2017)
Rigel Pharmaceuticals Inc, Ratio Charts
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report